Articles
-
Jun 3, 2024 |
elestoque.org | April Wang
Dear Meggie,Can you believe how many people still don’t know we’re twins? It seems strange, that you have always been a part of my life, and yet still, there is some part of the world that doesn’t know the two of us as a unit. When you’re a twin, you’re never alone: it’s so hard to be your own person. One of the oldest photos I can remember of us as children is of the two of us in matching polka-dot dresses, awkwardly posing just a little too far from each other to look natural.
-
May 26, 2024 |
elestoque.org | April Wang
Parent chats and networks, from organized WeChat and WhatsApp groups to parents simply talking to fellow parents online, are a common part of MVHS’s student culture. Senior Jennifer Long recalls her parents sharing information and advice that they learned from other parents through the chats almost daily. She notes that parents tend to share information about classes, college applications, various school or extracurricular teachers, school news and more.
-
Mar 28, 2024 |
biosimilardevelopment.com | Erich Bozenhardt |April Wang |Diane McCarthy |Li Jing
Don't get trapped in the misconception that only biomanufacturing process systems need maintenance. Here are some real-life examples of facility maintenance programs gone wrong. Pharma companies doing business in China have four key routes to register drugs faster than the standard ways. This discussion breaks down accelerated pathways and offers tips on how to approach them. When characterizing PQAs, the multi-attribute method offers a one-stop shop for analysis.
-
Mar 8, 2024 |
clinicalleader.com | April Wang
By April Wang, Accestra Consulting Company China's pharmaceutical market, the second largest in the world after the United States, is a hotspot for international pharmaceutical companies. As they seek to tap into this vast market, understanding the regulatory landscape and approval pathways is crucial. In this article, we will delve into the standard biologics approval procedures in China and explore accelerated pathways that can expedite the entry of certain products into the country.
-
Mar 8, 2024 |
biosimilardevelopment.com | April Wang
Get more biosimilar development insight with our FREE newsletter Guest Column | March 8, 2024 By April Wang, Accestra Consulting Company China's pharmaceutical market, the second largest in the world after the United States, is a hotspot for international pharmaceutical companies. As they seek to tap into this vast market, understanding the regulatory landscape and approval pathways is crucial.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →